ZESTAGEN
Zestagen is a Swiss biotechnology company developing light chain mAbs against Extracellular Heat Shock Protein-90 (ehsp90). hsp90 is a validated pharmaceutical target. ehsp90 is implicated in cancer cell motility, migration and metastasis. It is detectable at the surface of several cancer cells but not of normal adult cells. Zestagen's mAbs bind ehsp90 at the surface of cancer cells (but not normal cells) leading to significant inhibition of metastasis in preclinical cancer animal models. Unlike small molecule hsp90 inhibitors which do not discriminate between the extracellular and intracellular hsp90 pool, Zestagen’s mAbs are predicted to display a superior therapeutic index in cancer patients.
ZESTAGEN
Industry:
Biotechnology Health Diagnostics Pharmaceutical
Founded:
2011-01-01
Address:
Epalinges, Vaud, Switzerland
Country:
Switzerland
Website Url:
http://www.zestagen.com
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Amazon Nginx Amazon Frankfurt Region
Similar Organizations
Algonist Biotechnologies
Algonist Biotechnologies is a pre-clinical stage biotechnology company, developing novel small molecule therapeutics for chronic pain.
Roche France
Roche Diagnostics France is a biotechnology company that focuses on the research and development of pharmaceuticals and diagnostics.
Official Site Inspections
http://www.zestagen.com
- Host name: ec2-54-243-117-197.compute-1.amazonaws.com
- IP address: 54.243.117.197
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Zestagen"
Zetagen | Our Company | About Zetagen | Private Clinical-Stage …
Zetagen Founded in 2015, Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company dedicated to developing breakthrough therapies via local administration for …See details»
ZetaGen Therapeutics - Crunchbase Company Profile
ZetaGen Therapeutics may be growing as it successfully raised $9.79 million in a Series B funding round, which is a significant financial milestone indicating …See details»
ZetaGen Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
May 7, 2025 About Zetagen Therapeutics Founded in 2015, Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company dedicated to developing proprietary carriers …See details»
ZetaGen Company Profile - MedTech Innovator
ZetaGen’s first product, ZetaFuse™, is a drug-device combination product that has been designated as a device by FDA and utilizes components with well-established clinical safety …See details»
Zetagen Therapeutics Company Profile | Management and
Zetagen Therapeutics Profile and History Zetagen is a private, clinical-stage pharmaceutical company that develops innovative treatments for cancer and osteologic interventions. They …See details»
Zetagen Therapeutics Announces Successful Completion of …
May 6, 2025 Founded in 2015, Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company dedicated to developing breakthrough therapies via local …See details»
Zetagen Therapeutics Company Profile - Office Locations ... - Craft
Zetagen Therapeutics has 5 employees at their 1 location. See insights on Zetagen Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Zetagen Therapeutics - VentureRadar
"Zetagen Therapeutics is a clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic cancers to bone and other organs as …See details»
Zetagen | Home | Innovative Cancer Treatments & osteologic …
Zetagen is a private, clinical-stage pharmaceutical company developing innovative cancer treatments alongside osteologic interventions.See details»
ZetaGen Therapeutics 2025 Company Profile: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for ZetaGen Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Zestagen - Crunchbase Company Profile & Funding
Zestagen is a Swiss biotechnology company developing light chain mAbs against Extracellular Heat Shock Protein-90 (ehsp90).See details»
Zetagen Therapeutics Inc. Profile - Medical XPRT
Founded in 2015, Zetagen is a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic …See details»
Zestagen Company Profile | Management and Employees List
Zestagen Profile and History Zestagen SA, a portfolio company of Ventac Partners, is a Swiss anti-cancer biotechnology company. Our vision is to become a leading therapeutic company …See details»
Zetagen | Research Overview | Compassionate Use Access
The research behind Zetagen. Preclinical research resulting in a Breakthrough Device Designation award to ZetaMet for metastatic breast cancerSee details»
ZetaGen Therapeutics - Funding, Financials, Valuation & Investors
ZetaGen Therapeutics is funded by 4 investors. Consolidated Investment Group and New York Ventures are the most recent investors. Which investors participated in the most funding rounds?See details»
Zetagen Therapeutics Announces Peer-reviewed Publication of In …
Jun 17, 2025 Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company developing first-of-its-kind targeted therapies for primary and metastatic breast ...See details»
Zetagen | News | Keep up to date with the latest from Zetagen …
Zetagen | News | The latest Press Releases, Patent Information, Funding announcements about inductive biologic treatments from Zetagen.See details»
ZetaGen Therapeutics - Contacts, Employees, Board Members, …
ZetaGen Therapeutics commercializes a small molecule-based osteoinductive platform.See details»
Zetagen Therapeutics to conduct a Phase 2a study of ZetaMet™
Jun 17, 2025 Zetagen Therapeutics, Inc. announced today that they have successfully completed enrollment in their phase 2a study, which will evaluate ZetaMet™ (Zeta-BC-003) in …See details»
Walk With You | Zetagen
At Zetagen, we do what we do because we commit to Walk with You. Our first “Compassionate Use” patient was Colleen Connor. This is her story: As we walked with Colleen, we journeyed …See details»